Testosterone and aging male, a perspective from a developing country

References

• Kanabar R, Mazur A, Plum A, et al. Correlates of testosterone change as men age. Aging Male. 2022;25(1):29–40. doi: 10.1080/13685538.2021.2023493.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Corona G, Maggi M. Testosterone and sexual function in men. Maturitas. 2018;112:46–52. doi: 10.1016/j.maturitas.2018.04.004.
   PubMed Web of Science ®Google Scholar
• Jordan K, Fromberger P, Stolpmann G, et al. The role of testosterone in sexuality and paraphilia—a neurobiological approach. Part I: testosterone and sexuality. J Sex Med. 2011;8(11):2993–3007. doi: 10.1111/j.1743-6109.2011.02394.x.
   PubMed Web of Science ®Google Scholar
• Blute M, Hakimian P, Kashanian J, et al. Erectile dysfunction and testosterone deficiency. In: jones TH, editor. Front Horm Res. 2008;37:108–122.
   Google Scholar
• Corona G, Filippi S, Comelio P, et al. Sexual function in men undergoing androgen deprivation therapy. Int J Impot Res. 2021;33(4):439–447. doi: 10.1038/s41443-021-00418-7.
   PubMed Web of Science ®Google Scholar
• Donovan KA, Gonzalez BD, Nelson AM, et al. Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: a controlled comparison. Psychooncology. 2018;27(1):316–324. doi: 10.1002/pon.4463.
   PubMed Web of Science ®Google Scholar
• Skakkebæk A, Moore PJ, Chang S, et al. Quality of life in men with Klinefelter syndrome: the impact of genotype, health, socioeconomics, and sexual function. Genet Med. 2018;20(2):214–222. doi: 10.1038/gim.2017.110.
   PubMed Web of Science ®Google Scholar
• Boehm U, Bouloux P-M, Dattani MT, et al. European consensus statement on congenital hypogonadotropic hypogonadism—pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2015;11(9):547–564. doi: 10.1038/nrendo.2015.112.
   PubMed Web of Science ®Google Scholar
• Corona G, Lee DM, Forti G, et al. Age-related changes in general and sexual health in Middle-Aged and older men: results from the European male ageing study (EMAS). J Sex Med. 2010;7(4 Pt 1):1362–1380. doi: 10.1111/j.1743-6109.2009.01601.x.
   PubMed Web of Science ®Google Scholar
• Travison TG, Sand MS, Rosen RC, et al. The natural progression and regression of erectile dysfunction: follow-up results from the MMAS and MALES studies. J Sex Med. 2011;8(7):1917–1924. doi: 10.1111/j.1743-6109.2011.02294.x.
   PubMed Web of Science ®Google Scholar
• Helgason AR, Adolfsson J, Dickman P, et al. Sexual desire, erection, orgasm and ejaculatory functions and their importance to elderly Swedish men: a population-based study. Age Ageing. 1996;25(4):285–291. doi: 10.1093/ageing/25.4.285.
   PubMed Web of Science ®Google Scholar
• Gray A, Feldman HA, Mckinlay JB, et al. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts male aging study. J Clin Endocrinol Metab. 1991;73(5):1016–1025. doi: 10.1210/jcem-73-5-1016.
   PubMed Web of Science ®Google Scholar
• Sansone A, Mollaioli D, Ciocca G, et al. Sexual dysfunction in men and women with diabetes: a reflection of their complications? Curr Diabetes Rev. 2022;18:e030821192147.
   PubMed Web of Science ®Google Scholar
• Sansone A, Reisman Y, Jannini EA. Relationship between hyperuricemia with deposition and sexual dysfunction in males and females. J Endocrinol Invest. 2022;45(4):691–703. doi: 10.1007/s40618-021-01719-w.
   PubMed Web of Science ®Google Scholar
• Sansone A, Romanelli F, Gianfrilli D, et al. Endocrine evaluation of erectile dysfunction. Endocrine. 2014;46(3):423–430. doi: 10.1007/s12020-014-0254-6.
   PubMed Web of Science ®Google Scholar
• Golan R, Scovell JM, Ramasamy R. Age-related testosterone decline is due to waning of both testicular and hypothalamic-pituitary function. Aging Male. 2015;18(3):201–204. doi: 10.3109/13685538.2015.1052392.
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91(11):4335–4343. doi: 10.1210/jc.2006-0401.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Corona G, Tarocchi M, et al. How to define hypogonadism? Results from a population of men consulting for sexual dysfunction. J Endocrinol Invest. 2016;39(4):473–484. doi: 10.1007/s40618-015-0425-1.
   PubMed Web of Science ®Google Scholar
• Guay AT. Testosterone and erectile physiology. Aging Male. 2006;9(4):201–206. doi: 10.1080/13685530601051155.
   PubMed Web of Science ®Google Scholar
• Morelli A, Filippi S, Mancina R, et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology. 2004;145(5):2253–2263. doi: 10.1210/en.2003-1699.
   PubMed Web of Science ®Google Scholar
• Corona G, Torres LO, Maggi M. Testosterone therapy: what we have learned from trials. J Sex Med. 2020;17(3):447–460. doi: 10.1016/j.jsxm.2019.11.270.
   PubMed Web of Science ®Google Scholar
• Corona G, Isidori AM, Buvat J, et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med. 2014;11(6):1577–1592. doi: 10.1111/jsm.12536.
   PubMed Web of Science ®Google Scholar
• Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf). 2005;63(4):381–394. doi: 10.1111/j.1365-2265.2005.02350.x.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Morgentaler A, et al. Meta-analysis of results of testosterone therapy on sexual function based on international index of erectile function scores. Eur Urol. 2017;72(6):1000–1011. doi: 10.1016/j.eururo.2017.03.032.
   PubMed Web of Science ®Google Scholar
• Cunningham GR, Stephens-Shields AJ, Rosen RC, et al. Testosterone treatment and sexual function in older men with low testosterone levels. J Clin Endocrinol Metab. 2016;101(8):3096–3104. doi: 10.1210/jc.2016-1645.
   PubMed Web of Science ®Google Scholar
• Mazza AD, Morley JE. Metabolic syndrome and the older male population. Aging Male. 2007;10(1):3–8. doi: 10.1080/13685530701249592.
   PubMed Web of Science ®Google Scholar
• Alberti KGMM, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. Lancet. 2005;366(9491):1059–1062. doi: 10.1016/S0140-6736(05)67402-8.
   PubMed Web of Science ®Google Scholar
• Yang Y-H, Zhao M-J, Zhou S-J, et al. Is serum sex hormone-binding globulin a dominant risk factor for metabolic syndrome? Asian J Androl. 2015;17(6):991–995. doi: 10.4103/1008-682X.150845.
   PubMed Web of Science ®Google Scholar
• Moon H, Choi I, Kim S, et al. Cross-sectional association between testosterone, sex hormone-binding globulin and metabolic syndrome: the healthy twin study. Clin Endocrinol. 2017;87(5):523–531. doi: 10.1111/cen.13390.
   PubMed Web of Science ®Google Scholar
• Blaya R, Thomaz LDGR, Guilhermano F, et al. Total testosterone levels are correlated to metabolic syndrome components. Aging Male. 2016;19(2):85–89. doi: 10.3109/13685538.2016.1154523.
   PubMed Web of Science ®Google Scholar
• Antonio L, Wu FCW, O'Neill TW, et al. Associations between sex steroids and the development of metabolic syndrome: a longitudinal study in European men. J Clin Endocrinol Metab. 2015;100(4):1396–1404. doi: 10.1210/jc.2014-4184.
   PubMed Web of Science ®Google Scholar
• Grosman H, Rosales M, Fabre B, et al. Association between testosterone levels and the metabolic syndrome in adult men. Aging Male. 2014;17(3):161–165. doi: 10.3109/13685538.2014.913561.
   PubMed Web of Science ®Google Scholar
• Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27(5):1036–1041. doi: 10.2337/diacare.27.5.1036.
   PubMed Web of Science ®Google Scholar
• Tang Y-J, Lee W-J, Chen Y-T, et al. Serum testosterone level and related metabolic factors in men over 70 years old. J Endocrinol Invest. 2007;30(6):451–458. doi: 10.1007/BF03346327.
   PubMed Web of Science ®Google Scholar
• Zhou Y-H, Guo Y, Wang F, et al. Association of sex hormones and fat distribution in men with different obese and metabolic statuses. Int J Gen Med. 2022;15:1225–1238. doi: 10.2147/IJGM.S351282.
   PubMed Web of Science ®Google Scholar
• Zhong S-R, Yang H-H, Liao C-H, et al. Association between low serum testosterone and the development of metabolic syndrome in elderly Taiwanese men. Diabetes Metab Syndr Obes. 2021;14:99–106. doi: 10.2147/DMSO.S282832.
   PubMed Web of Science ®Google Scholar
• Chen RYT, Wittert GA, Andrews GR. Relative androgen deficiency in relation to obesity and metabolic status in older men. Diabetes Obes Metab. 2006;8(4):429–435. doi: 10.1111/j.1463-1326.2005.00532.x.
   PubMed Web of Science ®Google Scholar
• Mohr BA, Guay AT, O'Donnell AB, et al. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts male ageing study. Clin Endocrinol. 2005;62(1):64–73. doi: 10.1111/j.1365-2265.2004.02174.x.
   PubMed Web of Science ®Google Scholar
• Cheng J, Han B, Li Q, et al. Testosterone: relationships with metabolic disorders in men-An observational study from SPECT-China. Int J Endocrinol. 2017;2017:4547658. doi: 10.1155/2017/4547658.
   PubMed Web of Science ®Google Scholar
• Singh R, Artaza JN, Taylor WE, et al. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology. 2003;144(11):5081–5088. doi: 10.1210/en.2003-0741.
   PubMed Web of Science ®Google Scholar
• Singh R, Artaza JN, Taylor WE, et al. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with β-Catenin and T-Cell factor 4 may bypass canonical wnt signaling to down-regulate adipogenic transcription factors. Endocrinology. 2006;147(1):141–154. doi: 10.1210/en.2004-1649.
   PubMed Web of Science ®Google Scholar
• Carrageta DF, Oliveira PF, Alves MG, et al. Obesity and male hypogonadism: tales of a vicious cycle. Obes Rev off J Int Assoc Study Obes. 2019;20:1148–1158.
   Google Scholar
• Saad F, Yassin AA, Haider A, et al. Effects of testosterone on the lower urinary tract go beyond the prostate: new insights, new treatment options. Arab J Urol. 2011;9(2):147–152. doi: 10.1016/j.aju.2011.06.003.
   PubMedGoogle Scholar
• Smith U, Kahn BB. Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids. J Intern Med. 2016;280(5):465–475. doi: 10.1111/joim.12540.
   PubMed Web of Science ®Google Scholar
• Antinozzi C, Marampon F, Corinaldesi C, et al. Testosterone insulin-like effects: an in vitro study on the short-term metabolic effects of testosterone in human skeletal muscle cells. J Endocrinol Invest. 2017;40(10):1133–1143. doi: 10.1007/s40618-017-0686-y.
   PubMed Web of Science ®Google Scholar
• Isidori AM, Caprio M, Strollo F, et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab. 1999;84:3673–3680.
   PubMed Web of Science ®Google Scholar
• Russell SH, Small CJ, Stanley SA, et al. The in vitro role of tumour necrosis factor-alpha and interleukin-6 in the hypothalamic-pituitary gonadal axis. J Neuroendocrinol. 2001;13(3):296–301. doi: 10.1046/j.1365-2826.2001.00632.x.
   PubMed Web of Science ®Google Scholar
• Pivonello R, Menafra D, Riccio E, et al. Metabolic disorders and male hypogonadotropic hypogonadism. Front Endocrinol. 2019;10:345. doi: 10.3389/fendo.2019.00345.
   PubMed Web of Science ®Google Scholar
• Wittert G, Grossmann M. Obesity, type 2 diabetes, and testosterone in ageing men. Rev Endocr Metab Disord. 2022;23(6):1233–1242. doi: 10.1007/s11154-022-09746-5.
   PubMed Web of Science ®Google Scholar
• Cunningham GR. Testosterone and metabolic syndrome. Asian J Androl. 2015;17(2):192–196. doi: 10.4103/1008-682X.148068.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Tolrà J, Torremadé Barreda J, del Rio L, et al. Effects of testosterone treatment on body composition in males with testosterone deficiency syndrome. Aging Male. 2013;16(4):184–190. doi: 10.3109/13685538.2013.839648.
   PubMed Web of Science ®Google Scholar
• Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34(4):828–837. doi: 10.2337/dc10-1233.
   PubMed Web of Science ®Google Scholar
• Corona G, Giagulli VA, Maseroli E, et al. THERAPY oF ENDOCRINE DISEASE: testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174(3):R99–116. doi: 10.1530/EJE-15-0262.
   PubMed Web of Science ®Google Scholar
• Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272–283. doi: 10.1111/j.1743-6109.2010.01991.x.
   PubMed Web of Science ®Google Scholar
• Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021;9(1):32–45. doi: 10.1016/S2213-8587(20)30367-3.
   PubMed Web of Science ®Google Scholar
• Dang AK, Le HT, Nguyen GT, et al. Prevalence of metabolic syndrome and its related factors among vietnamese people: a systematic review and meta-analysis. Diabetes Metab Syndr. 2022;16(4):102477. doi: 10.1016/j.dsx.2022.102477.
   PubMed Web of Science ®Google Scholar
• Laurent MR, Dedeyne L, Dupont J, et al. Age-related bone loss and sarcopenia in men. Maturitas. 2019;122:51–56. doi: 10.1016/j.maturitas.2019.01.006.
   PubMed Web of Science ®Google Scholar
• Vescini F, Chiodini I, Falchetti A, et al. Management of osteoporosis in men: a narrative review. IJMS. 2021;22(24):13640. doi: 10.3390/ijms222413640.
   Google Scholar
• Fink HA, Ewing SK, Ensrud KE, et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab. 2006;91(10):3908–3915. doi: 10.1210/jc.2006-0173.
   PubMed Web of Science ®Google Scholar
• Mellström D, Johnell O, Ljunggren Ö, et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: mrOS Sweden. J Bone Miner Res. 2006;21(4):529–535. doi: 10.1359/jbmr.060110.
   PubMed Web of Science ®Google Scholar
• Spry NA, Galvão DA, Davies R, et al. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study. BJU Int. 2009;104(6):806–812. doi: 10.1111/j.1464-410X.2009.08458.x.
   PubMed Web of Science ®Google Scholar
• Chernichenko OA, Sakalo VS, Yakovlev PG, et al. Effect of androgen suppression on bone mineral density in patients with prostate cancer. Exp Oncol. 2014;36(4):276–278.
   Google Scholar
• Yu EY, Kuo KF, Gulati R, et al. Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, Hormone-Sensitive prostate cancer. J Clin Oncol. 2012;30(15):1864–1870. doi: 10.1200/JCO.2011.38.3745.
   PubMed Web of Science ®Google Scholar
• Vandenput L, Ohlsson C. Sex steroid metabolism in the regulation of bone health in men. J Steroid Biochem Mol Biol. 2010;121(3-5):582–588. doi: 10.1016/j.jsbmb.2010.03.067.
   PubMed Web of Science ®Google Scholar
• Chen Q, Kaji H, Sugimoto T, et al. Testosterone inhibits osteoclast formation stimulated by parathyroid hormone through androgen receptor. FEBS Lett. 2001;491(1-2):91–93. doi: 10.1016/s0014-5793(01)02160-3.
   PubMed Web of Science ®Google Scholar
• Kang H-Y, Cho C-L, Huang K-L, et al. Nongenomic androgen activation of phosphatidylinositol 3-kinase/akt signaling pathway in MC3T3-E1 osteoblasts. J Bone Miner Res. 2004;19(7):1181–1190. doi: 10.1359/JBMR.040306.
   PubMed Web of Science ®Google Scholar
• Benito M, Vasilic B, Wehrli FW, et al. Effect of testosterone replacement on trabecular architecture in hypogonadal men. J Bone Miner Res. 2005;20(10):1785–1791. doi: 10.1359/JBMR.050606.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Kang D, Li H. The effects of testosterone on bone health in males with testosterone deficiency: a systematic review and meta-analysis. BMC Endocr Disord. 2020;20(1):33. doi: 10.1186/s12902-020-0509-6.
   PubMed Web of Science ®Google Scholar
• Groti Antonič K. Impact of testosterone therapy on bone turnover markers in obese males with type 2 diabetes and functional hypogonadism. Aging Male. 2022;25(1):269–277. doi: 10.1080/13685538.2022.2134338.
   PubMed Web of Science ®Google Scholar
• Ng Tang Fui M, Hoermann R, Bracken K, et al. Effect of testosterone treatment on bone microarchitecture and bone mineral density in men: a 2-year RCT. J Clin Endocrinol Metab. 2021;106(8):e3143–e3158. doi: 10.1210/clinem/dgab149.
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern Med. 2017;177(4):471–479. doi: 10.1001/jamainternmed.2016.9539.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Tolrà J, Torremadé J, di Gregorio S, et al. Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome. Andrology. 2013;1(4):570–575. doi: 10.1111/j.2047-2927.2013.00090.x.
   PubMed Web of Science ®Google Scholar
• Shigehara K, Konaka H, Koh E, et al. Effects of testosterone replacement therapy on hypogonadal men with osteopenia or osteoporosis: a subanalysis of a prospective randomized controlled study in Japan (EARTH study). Aging Male. 2017;20(3):139–145. doi: 10.1080/13685538.2017.1303829.
   Web of Science ®Google Scholar
• Akishita M, Hashimoto M, Ohike Y, et al. Low testosterone level as a predictor of cardiovascular events in japanese men with coronary risk factors. Atherosclerosis. 2010;210(1):232–236. doi: 10.1016/j.atherosclerosis.2009.10.037.
   PubMed Web of Science ®Google Scholar
• Yeap BB, Hyde Z, Almeida OP, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab. 2009;94(7):2353–2359. doi: 10.1210/jc.2008-2416.
   PubMed Web of Science ®Google Scholar
• Shores MM, Biggs ML, Arnold AM, et al. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. J Clin Endocrinol Metab. 2014;99(6):2061–2068. doi: 10.1210/jc.2013-3576.
   PubMed Web of Science ®Google Scholar
• Khaw K-T, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in norfolk (EPIC-Norfolk) prospective population study. Circulation. 2007;116(23):2694–2701. doi: 10.1161/CIRCULATIONAHA.107.719005.
   PubMed Web of Science ®Google Scholar
• Cheetham TC, An J, Jacobsen SJ, et al. Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency. JAMA Intern Med. 2017;177(4):491–499. doi: 10.1001/jamainternmed.2016.9546.
   PubMed Web of Science ®Google Scholar
• Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110(7):1493–1500. doi: 10.1002/cncr.22933.
   PubMed Web of Science ®Google Scholar
• Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–4456. doi: 10.1200/JCO.2006.06.2497.
   PubMed Web of Science ®Google Scholar
• Zareba P, Duivenvoorden W, Leong DP, et al. Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol. 2016;8(2):118–129. doi: 10.1177/1756287215617872.
   PubMed Web of Science ®Google Scholar
• Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American heart association, American cancer society, and American urological association: endorsed by the American Society for radiation oncology. Circulation. 2010;121(6):833–840. doi: 10.1161/CIRCULATIONAHA.109.192695.
   PubMed Web of Science ®Google Scholar
• Elagizi A, Köhler TS, Lavie CJ. Testosterone and cardiovascular health. Mayo Clin Proc. 2018;93(1):83–100. doi: 10.1016/j.mayocp.2017.11.006.
   PubMed Web of Science ®Google Scholar
• Yeap BB, Marriott RJ, Antonio L, et al. Associations of serum testosterone and sex hormone-binding globulin with incident cardiovascular events in middle-aged to older men. Ann Intern Med. 2022;175(2):159–170. doi: 10.7326/M21-0551.
   PubMed Web of Science ®Google Scholar
• Marriott RJ, Harse J, Murray K, et al. Systematic review and meta-analyses on associations of endogenous testosterone concentration with health outcomes in community-dwelling men. BMJ Open. 2021;11(11):e048013. doi: 10.1136/bmjopen-2020-048013.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Di Pasquale G, et al. Endogenous testosterone levels and cardiovascular risk: meta-analysis of observational studies. J Sex Med. 2018;15(9):1260–1271. doi: 10.1016/j.jsxm.2018.06.012.
   PubMed Web of Science ®Google Scholar
• Ruige JB, Mahmoud AM, De Bacquer D, et al. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart. 2011;97(11):870–875. doi: 10.1136/hrt.2010.210757.
   PubMed Web of Science ®Google Scholar
• Traish AM, Guay A, Feeley R, et al. The dark side of testosterone deficiency: i. Metabolic syndrome and erectile dysfunction. J Androl. 2009;30(1):10–22. doi: 10.2164/jandrol.108.005215.
   PubMed Web of Science ®Google Scholar
• Mäkinen J, Järvisalo MJ, Pöllänen P, et al. Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol. 2005;45(10):1603–1608. doi: 10.1016/j.jacc.2005.01.052.
   PubMed Web of Science ®Google Scholar
• Muller M, van den Beld AW, Bots ML, et al. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004;109(17):2074–2079. doi: 10.1161/01.CIR.0000125854.51637.06.
   PubMed Web of Science ®Google Scholar
• Soisson V, Brailly-Tabard S, Empana J-P, et al. Low plasma testosterone and elevated carotid intima-media thickness: importance of low-grade inflammation in elderly men. Atherosclerosis. 2012;223(1):244–249. doi: 10.1016/j.atherosclerosis.2012.05.009.
   PubMed Web of Science ®Google Scholar
• Jones TH. Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab. 2010;21(8):496–503. doi: 10.1016/j.tem.2010.03.002.
   PubMed Web of Science ®Google Scholar
• Lu Y-L, Kuang L, Zhu H, et al. Changes in aortic endothelium ultrastructure in male rats following castration, replacement with testosterone and administration of 5alpha-reductase inhibitor. Asian J Androl. 2007;9(6):843–847. doi: 10.1111/j.1745-7262.2007.00327.x.
   PubMed Web of Science ®Google Scholar
• Hotta Y, Kataoka T, Kimura K. Testosterone deficiency and endothelial dysfunction: nitric oxide, asymmetric dimethylarginine, and endothelial progenitor cells. Sex Med Rev. 2019;7(4):661–668. doi: 10.1016/j.sxmr.2019.02.005.
   PubMed Web of Science ®Google Scholar
• Budoff MJ, Ellenberg SS, Lewis CE, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA. 2017;317(7):708–716. doi: 10.1001/jama.2016.21043.
   PubMed Web of Science ®Google Scholar
• Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–1836. doi: 10.1001/jama.2013.280386.
   PubMed Web of Science ®Google Scholar
• Zhang X, Huang K, Saad F, et al. Testosterone therapy reduces cardiovascular risk among hypogonadal men: a prospective cohort study in Germany. Androg Clin Res Ther. 2021;2(1):64–72. doi: 10.1089/andro.2020.0015.
   Google Scholar
• Maggi M, Wu FCW, Jones TH, et al. Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the registry of hypogonadism in men (RHYME). Int J Clin Pract. 2016;70(10):843–852. doi: 10.1111/ijcp.12876.
   PubMed Web of Science ®Google Scholar
• Haider A, Yassin A, Haider KS, et al. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study. Vasc Health Risk Manag. 2016;12:251–261.
   PubMed Web of Science ®Google Scholar
• Kim S-D, Cho K-S. Obstructive sleep apnea and testosterone deficiency. World J Mens Health. 2019;37(1):12–18. doi: 10.5534/wjmh.180017.
   PubMedGoogle Scholar
• Cole AP, Hanske J, Jiang W, et al. Impact of testosterone replacement therapy on thromboembolism, heart disease and obstructive sleep apnoea in men. BJU Int. 2018;121(5):811–818. doi: 10.1111/bju.14149.
   PubMed Web of Science ®Google Scholar
• Payne K, Lipshultz LI, Hotaling JM, et al. Obstructive sleep apnea and testosterone therapy. Sex Med Rev. 2021;9(2):296–303. doi: 10.1016/j.sxmr.2020.04.004.
   PubMed Web of Science ®Google Scholar
• Salonia A, Bettocchi C, Boeri L, et al. European association of urology guidelines on sexual and reproductive health-2021 update: male sexual dysfunction. Eur Urol. 2021;80(3):333–357. doi: 10.1016/j.eururo.2021.06.007.
   PubMed Web of Science ®Google Scholar
• Bachman E, Travison TG, Basaria S, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. J Gerontol A Biol Sci Med Sci. 2014;69(6):725–735. doi: 10.1093/gerona/glt154.
   PubMed Web of Science ®Google Scholar
• Maggio M, Snyder PJ, Ceda GP, et al. Is the haematopoietic effect of testosterone mediated by erythropoietin? The results of a clinical trial in older men. Andrology. 2013;1(1):24–28. doi: 10.1111/j.2047-2927.2012.00009.x.
   PubMed Web of Science ®Google Scholar
• Guralnik J, Ershler W, Artz A, et al. Unexplained anemia of aging: etiology, health consequences, and diagnostic criteria. J Am Geriatr Soc. 2022;70(3):891–899. doi: 10.1111/jgs.17565.
   PubMed Web of Science ®Google Scholar
• Domenica Cappellini M, Motta I. Anemia in clinical practice—definition and classification: does hemoglobin change with aging? Semin Hematol. 2015;52(4):261–269. doi: 10.1053/j.seminhematol.2015.07.006.
   PubMed Web of Science ®Google Scholar
• Awaluddin SM, Shahein NA, Che Abdul Rahim N, et al. Anemia among men in Malaysia: a population-based survey in 2019. IJERPH. 2021;18(20):10922. doi: 10.3390/ijerph182010922.
   Web of Science ®Google Scholar
• Ferrucci L, Maggio M, Bandinelli S, et al. Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med. 2006;166(13):1380–1388. doi: 10.1001/archinte.166.13.1380.
   PubMed Web of Science ®Google Scholar
• Shin YS, You JH, Cha JS, et al. The relationship between serum total testosterone and free testosterone levels with serum hemoglobin and hematocrit levels: a study in 1221 men. Aging Male. 2016;19(4):209–214. doi: 10.1080/13685538.2016.1229764.
   PubMed Web of Science ®Google Scholar
• Hicks BM, Klil-Drori AJ, Yin H, et al. Androgen deprivation therapy and the risk of anemia in men with prostate cancer. Epidemiology. 2017;28(5):712–718. doi: 10.1097/EDE.0000000000000678.
   PubMed Web of Science ®Google Scholar
• Gagliano-Jucá T, Pencina KM, Ganz T, et al. Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer. Am J Physiol Endocrinol Metab. 2018;315(6):E1185–E1193. doi: 10.1152/ajpendo.00272.2018.
   PubMed Web of Science ®Google Scholar
• Grossmann M, Zajac JD. Hematological changes during androgen deprivation therapy. Asian J Androl. 2012;14(2):187–192. doi: 10.1038/aja.2011.102.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi: 10.1210/jc.2018-00229.
   PubMed Web of Science ®Google Scholar
• Jones SD, Dukovac T, Sangkum P, et al. Erythrocytosis and polycythemia secondary to testosterone replacement therapy in the aging male. Sex Med Rev. 2015;3(2):101–112. doi: 10.1002/smrj.43.
   PubMedGoogle Scholar
• Calado RT, Yewdell WT, Wilkerson KL, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood. 2009;114(11):2236–2243. doi: 10.1182/blood-2008-09-178871.
   PubMed Web of Science ®Google Scholar
• Bachman E, Feng R, Travison T, et al. Testosterone suppresses hepcidin in men: a potential mechanism for Testosterone-Induced erythrocytosis. J Clin Endocrinol Metab. 2010;95(10):4743–4747. doi: 10.1210/jc.2010-0864.
   PubMed Web of Science ®Google Scholar
• Shahani S, Braga-Basaria M, Maggio M, et al. Androgens and erythropoiesis: past and present. J Endocrinol Invest. 2009;32(8):704–716. doi: 10.1007/BF03345745.
   PubMed Web of Science ®Google Scholar
• König CS, Balabani S, Hackett GI, et al. Testosterone therapy: an assessment of the clinical consequences of changes in hematocrit and blood flow characteristics. Sex Med Rev. 2019;7(4):650–660. doi: 10.1016/j.sxmr.2019.01.003.
   PubMed Web of Science ®Google Scholar
• Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in Middle-Aged and older men: a Meta-Analysis of randomized, Placebo-Controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60(11):1451–1457. doi: 10.1093/gerona/60.11.1451.
   PubMed Web of Science ®Google Scholar
• Salonia A, Bettochi C, Carvalho J, et al. EAU guidelines on sexual and reproductive health 2020. Eur assoc urol guidel. 2020 Ed. Arnhem, The Netherlands: European Association of Urology Guidelines Office; 2020.
   Google Scholar
• Hackett G, Kirby M, Edwards D, et al. British Society for sexual medicine guidelines on adult testosterone deficiency, with statements for UK practice. J Sex Med. 2017;14(12):1504–1523. doi: 10.1016/j.jsxm.2017.10.067.
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18(1):5–15. doi: 10.3109/13685538.2015.1004049.
   PubMed Web of Science ®Google Scholar
• Strange RC, König CS, Ahmed A, et al. Testosterone therapy: increase in hematocrit is associated with decreased mortality. Androg Clin Res Ther. 2021;2(1):150–159. doi: 10.1089/andro.2021.0019.
   Google Scholar
• Swerdloff RS, Wang C. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male. 2003;6(3):207–211. doi: 10.1080/tam.6.3.207.211.
   PubMedGoogle Scholar
• Nackeeran S, Kohn T, Gonzalez D, et al. The effect of route of testosterone on changes in hematocrit: a systematic review and Bayesian network Meta-Analysis of randomized trials. J Urol. 2022;207(1):44–51. doi: 10.1097/ju.0000000000002188.
   PubMedGoogle Scholar
• Snyder PJ, Bhasin S, Cunningham GR, et al. Lessons from the testosterone trials. Endocr Rev. 2018;39(3):369–386. doi: 10.1210/er.2017-00234.
   PubMed Web of Science ®Google Scholar
• Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis following testosterone therapy. Sex Med Rev. 2018;6(1):77–85. doi: 10.1016/j.sxmr.2017.04.001.
   PubMed Web of Science ®Google Scholar
• Albarqouni L, Sanders S, Clark J, et al. Self-management for men with lower urinary tract symptoms: a systematic review and meta-analysis. Ann Fam Med. 2021;19(2):157–167. doi: 10.1370/afm.2609.
   PubMed Web of Science ®Google Scholar
• Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44(6):637–649. doi: 10.1016/j.eururo.2003.08.015.
   PubMed Web of Science ®Google Scholar
• Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the health professionals follow-up study. Urology. 2002;59(2):245–250. doi: 10.1016/s0090-4295(01)01506-0.
   PubMed Web of Science ®Google Scholar
• Taylor BC, Wilt TJ, Fink HA, et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology. 2006;68(4):804–809. doi: 10.1016/j.urology.2006.04.019.
   PubMed Web of Science ®Google Scholar
• Speakman M, Kirby R, Doyle S, et al. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) – focus on the UK. BJU Int. 2015;115(4):508–519. doi: 10.1111/bju.12745.
   PubMed Web of Science ®Google Scholar
• Welén K, Damber J-E. Androgens, aging, and prostate health. Rev Endocr Metab Disord. 2022;23(6):1221–1231. doi: 10.1007/s11154-022-09730-z.
   PubMed Web of Science ®Google Scholar
• Xia B-W, Zhao S-C, Chen Z-P, et al. Relationship between serum total testosterone and prostate volume in aging men. Sci Rep. 2021;11(1):14122. doi: 10.1038/s41598-021-93728-1.
   PubMed Web of Science ®Google Scholar
• Schatzl G, Brössner C, Schmid S, et al. Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. Urology. 2000;55(3):397–402. doi: 10.1016/s0090-4295(99)00473-2.
   PubMed Web of Science ®Google Scholar
• Chang IH, Oh SY, Kim SC. A possible relationship between testosterone and lower urinary tract symptoms in men. J Urol. 2009;182(1):215–220. doi: 10.1016/j.juro.2009.02.123.
   PubMed Web of Science ®Google Scholar
• Trifiro MD, Parsons JK, Palazzi-Churas K, et al. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. BJU Int. 2010;105(11):1554–1559. doi: 10.1111/j.1464-410X.2009.09090.x.
   PubMed Web of Science ®Google Scholar
• Litman HJ, Bhasin S, O'Leary MP, et al. An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston area community health survey. BJU Int. 2007;100(2):321–326. doi: 10.1111/j.1464-410X.2007.06938.x.
   PubMed Web of Science ®Google Scholar
• Rohrmann S, Nelson WG, Rifai N, et al. Serum sex steroid hormones and lower urinary tract symptoms in third national health and nutrition examination survey (NHANES III). Urology. 2007;69(4):708–713. doi: 10.1016/j.urology.2007.01.011.
   PubMed Web of Science ®Google Scholar
• Rosenzweig BA, Bolina PS, Birch L, et al. Location and concentration of estrogen, progesterone, and androgen receptors in the bladder and urethra of the rabbit. Neurourol Urodyn. 1995;14(1):87–96. doi: 10.1002/nau.1930140114.
   PubMed Web of Science ®Google Scholar
• Salmi S, Santti R, Gustafsson J-Â, et al. Co-localization of androgen receptor with estrogen receptor β in the lower urinary tract of the male rat. J Urol. 2001;166(2):674–677. doi: 10.1016/S0022-5347(05)66041-7.
   PubMed Web of Science ®Google Scholar
• Yasui M, Kawahara T, Takamoto D, et al. Distribution of androgen receptor expression in the urinary bladder. Int J Urol. 2019;26(2):305–306. doi: 10.1111/iju.13841.
   PubMed Web of Science ®Google Scholar
• Ide H, Miyamoto H. The role of steroid hormone receptors in urothelial tumorigenesis. Cancers. 2020;12(8):2155. doi: 10.3390/cancers12082155.
   PubMed Web of Science ®Google Scholar
• Hall R, Andrews PLR, Hoyle CHV. Effects of testosterone on neuromuscular transmission in rat isolated urinary bladder. Eur J Pharmacol. 2002;449(3):301–309. doi: 10.1016/s0014-2999(02)02047-2.
   PubMed Web of Science ®Google Scholar
• Christ GJ, Andersson K-E. Rho-kinase and effects of rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn. 2007;26(6 Suppl):948–954. doi: 10.1002/nau.20475.
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Morelli A, Filippi S, et al. Testosterone regulates RhoA/rho-kinase signaling in two distinct animal models of chemical diabetes. J Sex Med. 2007;4(3):620–632. doi: 10.1111/j.1743-6109.2007.00440.x.
   PubMed Web of Science ®Google Scholar
• Shigehara K, Izumi K, Mizokami A, et al. Testosterone deficiency and nocturia: a review. World J Mens Health. 2017;35(1):14–21. doi: 10.5534/wjmh.2017.35.1.14.
   PubMedGoogle Scholar
• Traish AM, Johansen V. Impact of testosterone deficiency and testosterone therapy on lower urinary tract symptoms in men with metabolic syndrome. World J Mens Health. 2018;36(3):199–222. doi: 10.5534/wjmh.180032.
   PubMedGoogle Scholar
• Demir O, Akgul K, Akar Z, et al. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male. 2009;12(1):29–34. doi: 10.1080/13685530902777425.
   PubMed Web of Science ®Google Scholar
• Russo GI, Castelli T, Urzì D, et al. Connections between lower urinary tract symptoms related to benign prostatic enlargement and metabolic syndrome with its components: a systematic review and meta-analysis. Aging Male. 2015;18(4):207–216. doi: 10.3109/13685538.2015.1062980.
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Rastrelli G, Corona G, et al. Benign prostatic hyperplasia: a new metabolic disease? J Endocrinol Invest. 2014;37(4):313–322. doi: 10.1007/s40618-014-0051-3.
   PubMed Web of Science ®Google Scholar
• Fibbi B, Penna G, Morelli A, et al. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl. 2010;33(3):475–488. doi: 10.1111/j.1365-2605.2009.00972.x.
   PubMedGoogle Scholar
• Breyer BN, Sarma AV. Hyperglycemia and insulin resistance and the risk of BPH/LUTS: an update of recent literature. Curr Urol Rep. 2014;15(12):462. doi: 10.1007/s11934-014-0462-x.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55(2):310–320. doi: 10.1016/j.eururo.2008.09.024.
   PubMed Web of Science ®Google Scholar
• Kohn TP, Mata DA, Ramasamy R, et al. Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis. Eur Urol. 2016;69(6):1083–1090. doi: 10.1016/j.eururo.2016.01.043.
   PubMed Web of Science ®Google Scholar
• Cui Y, Zhang Y. The effect of androgen-replacement therapy on prostate growth: a systematic review and meta-analysis. Eur Urol. 2013;64(5):811–822. doi: 10.1016/j.eururo.2013.03.042.
   PubMed Web of Science ®Google Scholar
• Yassin D-J, El Douaihy Y, Yassin AA, et al. Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study. World J Urol. 2014;32(4):1049–1054. doi: 10.1007/s00345-013-1187-z.
   PubMed Web of Science ®Google Scholar
• Meuleman EJH, Legros J-J, Bouloux PMG, et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Aging Male. 2015;18(3):157–163. doi: 10.3109/13685538.2015.1032925.
   PubMed Web of Science ®Google Scholar
• Yucel C, Keskin MZ, Peskircioglu CL. The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Curr Urol. 2017;11(1):4–8. doi: 10.1159/000447187.
   PubMedGoogle Scholar
• Okada K, Miyake H, Ishida T, et al. Improved lower urinary tract symptoms associated with testosterone replacement therapy in japanese men with late-onset hypogonadism. Am J Mens Health. 2018;12(5):1403–1408. doi: 10.1177/1557988316652843.
   PubMed Web of Science ®Google Scholar
• Lim GY, Tam WW, Lu Y, et al. Prevalence of depression in the community from 30 countries between 1994 and 2014. Sci Rep. 2018;8(1):2861. doi: 10.1038/s41598-018-21243-x.
   PubMed Web of Science ®Google Scholar
• Khera M, Bhattacharya RK, Blick G, et al. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the testim registry in the US (TRiUS). Aging Male. 2012;15(1):14–21. doi: 10.3109/13685538.2011.606513.
   PubMed Web of Science ®Google Scholar
• Beutel ME, Glaesmer H, Wiltink J, et al. Life satisfaction, anxiety, depression and resilience across the life span of men. Aging Male. 2010;13(1):32–39. doi: 10.3109/13685530903296698.
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Kawa G, Kinoshita H, et al. Symptomatic change in Japanese hypogonadal patients several years after androgen replacement therapy. Aging Male. 2011;14(3):190–194. doi: 10.3109/13685538.2011.573028.
   PubMed Web of Science ®Google Scholar
• Wainberg M, Kloiber S, Diniz B, et al. Clinical laboratory tests and five-year incidence of major depressive disorder: A prospective cohort study of 433,890 participants from the UK biobank. Transl Psychiatry. 2021;11(1):380 10.1038/s41398-021-01505-5 PMC: 34234104
   PubMed Web of Science ®Google Scholar
• Ford AH, Yeap BB, Flicker L, et al. Prospective longitudinal study of testosterone and incident depression in older men: the health in men study. Psychoneuroendocrinology. 2016;64:57–65. doi: 10.1016/j.psyneuen.2015.11.012.
   PubMed Web of Science ®Google Scholar
• Pirkis J, Pfaff J, Williamson M, et al. The community prevalence of depression in older Australians. J Affect Disord. 2009;115(1-2):54–61. doi: 10.1016/j.jad.2008.08.014.
   PubMed Web of Science ®Google Scholar
• Sarokhani D, Parvareh M, Dehkordi AH, et al. Prevalence of depression among Iranian elderly: systematic review and meta-analysis. Iran J Psychiatry. 2018;13(1):55–64.
   Google Scholar
• Yeap BB. Hormonal changes and their impact on cognition and mental health of ageing men. Maturitas. 2014;79(2):227–235. doi: 10.1016/j.maturitas.2014.05.015.
   PubMed Web of Science ®Google Scholar
• Kaufman J-M, Lapauw B, Mahmoud A, et al. Aging and the male reproductive system. Endocr Rev. 2019;40(4):906–972. doi: 10.1210/er.2018-00178.
   PubMed Web of Science ®Google Scholar
• Berglund LH, Prytz HS, Perski A, et al. Testosterone levels and psychological health status in men from a general population: the tromsø study. Aging Male. 2011;14(1):37–41. doi: 10.3109/13685538.2010.522276.
   PubMed Web of Science ®Google Scholar
• Schneider G, Nienhaus K, Gromoll J, et al. Sex hormone levels, genetic androgen receptor polymorphism, and anxiety in ≥50-Year-Old males. J Sex Med. 2011;8(12):3452–3464. doi: 10.1111/j.1743-6109.2011.02443.x.
   PubMed Web of Science ®Google Scholar
• Pillerová M, Borbélyová V, Pastorek M, et al. Molecular actions of sex hormones in the brain and their potential treatment use in anxiety disorders. Front Psychiatry. 2022;13:972158. doi: 10.3389/fpsyt.2022.972158.
   PubMed Web of Science ®Google Scholar
• Kocoglu H, Alan C, Soydan H, et al. Association between the androgen levels and erectile function, cognitive functions and hypogonadism symptoms in aging males. Aging Male. 2011;14(4):207–212. doi: 10.3109/13685538.2011.617798.
   PubMed Web of Science ®Google Scholar
• Cai Z, Li H. An updated review: androgens and cognitive impairment in older men. Front Endocrinol (Lausanne). 2020;11:586909. doi: 10.3389/fendo.2020.586909.
   PubMed Web of Science ®Google Scholar
• Bianchi VE. Impact of testosterone on alzheimer’s disease. World J Mens Health. 2022;40(2):243–256. doi: 10.5534/wjmh.210175.
   PubMedGoogle Scholar
• Hsu B, Cumming RG, Waite LM, et al. Longitudinal relationships between reproductive hormones and cognitive decline in older men: the concord health and ageing in men project. J Clin Endocrinol Metab. 2015;100(6):2223–2230. doi: 10.1210/jc.2015-1016.
   PubMed Web of Science ®Google Scholar
• Yaffe K, Barnes D, Lindquist K, et al. Endogenous sex hormone levels and risk of cognitive decline in an older biracial cohort. Neurobiol Aging. 2007;28(2):171–178. doi: 10.1016/j.neurobiolaging.2006.10.004.
   PubMed Web of Science ®Google Scholar
• Kische H, Gross S, Wallaschofski H, et al. Associations of androgens with depressive symptoms and cognitive status in the general population. He B, editor. PLoS One. 2017;12(5):e0177272. doi: 10.1371/journal.pone.0177272.
   PubMed Web of Science ®Google Scholar
• Sarkey S, Azcoitia I, Garcia-Segura LM, et al. Classical androgen receptors in non-classical sites in the brain. Horm Behav. 2008;53(5):753–764. doi: 10.1016/j.yhbeh.2008.02.015.
   PubMed Web of Science ®Google Scholar
• Zitzmann M. Testosterone and the brain. Aging Male. 2006;9(4):195–199. doi: 10.1080/13685530601040679.
   PubMed Web of Science ®Google Scholar
• Mhaouty-Kodja S. Role of the androgen receptor in the central nervous system. Mol Cell Endocrinol. 2018;465:103–112. doi: 10.1016/j.mce.2017.08.001.
   PubMed Web of Science ®Google Scholar
• Hauger RL, Saelzler UG, Pagadala MS, et al. The role of testosterone, the androgen receptor, and hypothalamic–pituitary–gonadal axis in depression in ageing men. Rev Endocr Metab Disord. 2022;23(6):1259–1273. doi: 10.1007/s11154-022-09767-0.
   PubMed Web of Science ®Google Scholar
• Sheng Z, Kawano J, Yanai A, et al. Expression of estrogen receptors (α, β) and androgen receptor in serotonin neurons of the rat and mouse dorsal raphe nuclei; sex and species differences. Neurosci Res. 2004;49(2):185–196. doi: 10.1016/j.neures.2004.02.011.
   PubMed Web of Science ®Google Scholar
• Bianchi VE, Rizzi L, Bresciani E, et al. Androgen therapy in neurodegenerative diseases. J Endocr Soc. 2020;4:bvaa120.
   PubMed Web of Science ®Google Scholar
• Walther A, Breidenstein J, Miller R. Association of testosterone treatment with alleviation of depressive symptoms in men: a systematic review and meta-analysis. JAMA Psychiatry. 2019;76(1):31–40. doi: 10.1001/jamapsychiatry.2018.2734.
   PubMed Web of Science ®Google Scholar
• Tan S, Sohrabi HR, Weinborn M, et al. Effects of testosterone supplementation on separate cognitive domains in cognitively healthy older men: a meta-analysis of current randomized clinical trials. Am J Geriatr Psychiatry. 2019;27(11):1232–1246. doi: 10.1016/j.jagp.2019.05.008.
   PubMed Web of Science ®Google Scholar
• Nghia HT. The model of population transition in Vietnam in relation to Europe and Asia: a quantitative approach. J Asian Afr Stud. 2020;55(6):786–800. doi: 10.1177/0021909620935411.
   Web of Science ®Google Scholar
• Nguyen TT, Hoang MV. Non-communicable diseases, food and nutrition in Vietnam from 1975 to 2015: the burden and national response. Asia Pac J Clin Nutr. 2018;27:19–28.
   PubMed Web of Science ®Google Scholar
• Nguyen LT, Nantharath P, Kang E. The sustainable care model for an ageing population in Vietnam: evidence from a systematic review. Sustainability. 2022;14(5):2518. doi: 10.3390/su14052518.
   Web of Science ®Google Scholar
• Jannini EA. SM = SM: the interface of systems medicine and sexual medicine for facing non-communicable diseases in a gender-dependent manner. Sex Med Rev. 2017;5(3):349–364. doi: 10.1016/j.sxmr.2017.04.002.
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Trevisan M. Vietnam a country in transition: health challenges. BMJNPH. 2020;3(1):60–66. bmjnph. doi: 10.1136/bmjnph-2020-000069.
   Google Scholar
• Beia T, Kielmann K, Diaconu K. Changing men or changing health systems? A scoping review of interventions, services and programmes targeting men’s health in Sub-Saharan Africa. Int J Equity Health. 2021;20(1):87. doi: 10.1186/s12939-021-01428-z.
   PubMed Web of Science ®Google Scholar
• Ng CJ, Tan HM, Low WY. What do Asian men consider as important masculinity attributes? Findings from the Asian men’s attitudes to life events and sexuality (MALES) study. J Mens Health. 2008;5(4):350–355. doi: 10.1016/j.jomh.2008.10.005.
   Web of Science ®Google Scholar
• Ho CC, Singam P, Hong GE, et al. Male sexual dysfunction in Asia. Asian J Androl. 2011;13(4):537–542. doi: 10.1038/aja.2010.135.
   PubMed Web of Science ®Google Scholar
• Bhui K, Chandran M, Sathyamoorthy G. Mental health assessment and South Asian men. Int Rev Psychiatry. 2002;14(1):52–59. doi: 10.1080/09540260120114069.
   Web of Science ®Google Scholar
• Sansone A, Cuzin B, Jannini EA. Facing counterfeit medications in sexual medicine. A systematic scoping review on social strategies and technological solutions. Sex Med. 2021;9(6):100437. doi: 10.1016/j.esxm.2021.100437.
   PubMed Web of Science ®Google Scholar
• Chaubey SK, Sangla KS, Suthaharan EN, et al. Severe hypoglycaemia associated with ingesting counterfeit medication. Med J Aust. 2010;192(12):716–717. doi: 10.5694/j.1326-5377.2010.tb03710.x.
   PubMed Web of Science ®Google Scholar
• Kao SL, Chan CL, Tan B, et al. An unusual outbreak of hypoglycemia. N Engl J Med. 2009;360(7):734–736. doi: 10.1056/NEJMc0807678.
   PubMed Web of Science ®Google Scholar
• An Q, Gu Y-Q. Testosterone replacement therapy: dilemmas and challenges in China and Asia. Asian J Androl. 2018;20(2):149–151. doi: 10.4103/aja.aja_16_17.
   PubMed Web of Science ®Google Scholar
• Rehman SU, Choe K, Yoo HH. Review on a traditional herbal medicine, Eurycoma longifolia jack (tongkat ali): its traditional uses, chemistry, Evidence-Based pharmacology and toxicology. Molecules. 2016;21(3):331. doi: 10.3390/molecules21030331.
   PubMed Web of Science ®Google Scholar
• Lim PHC. Asian herbals and aphrodisiacs used for managing ED. Transl Androl Urol. 2017;6(2):167–175. doi: 10.21037/tau.2017.04.04.
   PubMed Web of Science ®Google Scholar
• Sun Y, Liu Z. Men’s health in China. J Mens Health Gend. 2007;4(1):13–17. doi: 10.1016/j.jmhg.2006.12.001.
   Google Scholar
• Jannini EA, Sternbach N, Limoncin E, et al. Health-related characteristics and unmet needs of men with erectile dysfunction: a survey in five european countries. J Sex Med. 2014;11(1):40–50. doi: 10.1111/jsm.12344.
   PubMed Web of Science ®Google Scholar
• Linhares BL, Miranda EP, Cintra AR, et al. Use, misuse and abuse of testosterone and other androgens. Sex Med Rev. 2022;10(4):583–595. doi: 10.1016/j.sxmr.2021.10.002.
   Web of Science ®Google Scholar
• Irwig MS, Fleseriu M, Jonklaas J, et al. Off-label use and misuse of testosterone, growth hormone, thyroid hormone, and adrenal supplements: risks and costs of a growing problem. Endocr Pract. 2020;26(3):340–353. doi: 10.4158/PS-2019-0540.
   PubMed Web of Science ®Google Scholar
• Baillargeon J, Urban RJ, Kuo Y-F, et al. Screening and monitoring in men prescribed testosterone therapy in the U.S., 2001–2010. Public Health Rep. 2015;130(2):143–152. doi: 10.1177/003335491513000207.
   PubMed Web of Science ®Google Scholar
• Crosnoe LE, Grober E, Ohl D, et al. Exogenous testosterone: a preventable cause of male infertility. Transl Androl Urol. 2013;2:10613–10113.
   Google Scholar
• Ko EY, Siddiqi K, Brannigan RE, et al. Empirical medical therapy for idiopathic male infertility: a survey of the American urological association. J Urol. 2012;187(3):973–978. doi: 10.1016/j.juro.2011.10.137.
   PubMed Web of Science ®Google Scholar
• Bond P, Smit DL, de Ronde W. Anabolic-androgenic steroids: how do they work and what are the risks? Front Endocrinol. 2022;13:1059473.
   PubMed Web of Science ®Google Scholar
• Terreros JL, Manonelles P, López-Plaza D. Relationship between doping prevalence and socioeconomic parameters: an analysis by sports categories and world areas. IJERPH. 2022;19(15):9329. doi: 10.3390/ijerph19159329.
   Web of Science ®Google Scholar
• Yang C-FJ, Gray P, Pope HG. Male body image in Taiwan versus the west: yanggang zhiqi meets the adonis complex. Am J Psychiatry. 2005;162(2):263–269. doi: 10.1176/appi.ajp.162.2.263.
   PubMed Web of Science ®Google Scholar
• Sagoe D, Molde H, Andreassen CS, et al. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol. 2014;24(5):383–398. doi: 10.1016/j.annepidem.2014.01.009.
   PubMed Web of Science ®Google Scholar
• Kanayama G, Hudson JI, Pope HG. Jr HGP. Culture, psychosomatics and substance abuse: the example of body image drugs. Psychother Psychosom. 2012;81(2):73–78., doi: 10.1159/000330415.
   PubMed Web of Science ®Google Scholar